Pay in 4 interest-free payments of $6.25 Learn more
Ships within 48 hours · Estimated delivery Jul 27 - Aug 1
Structure-Based Design of an in Vivo Active Selective BRD9 Inhibitor
Destabilization of both β-catenin and Ras via targeting axin is a potential therapeutic strategy for treatment of CRC and other type cancers activated Wnt/β-catenin and Ras pathways
86(3):194-9
is a highly potent and selective small molecule that promotes pancreatic β cell proliferation in rodent and human primary islets
Tyrosine kinase inhibitor SU11274 increased tumorigenicity and enriched for melanoma-initiating cells by bioenergetic modulation
BAY-57-1293 - CAS# 348086-71-5 size:10mg solid Structure-Based Design of an inBAY 57 1293, CAS No. 348086 71 5, is a potent helicase primase inhibitor. BAY 57 1293 inhibits replication of herpes simplex virus (HSV) type 1 and type 2 in the nanomolar range in vitro by abrogating the enzymatic activity of the viral primase helicase complex. In various rodent models of HSV infection the antiviral activity of BAY 57 1293 in vivo was found to be superior compared to all compounds currently used to treat HSV infections. The compound
US$ 1745.76
US$ 24.95
US$ 13.95
US$ 19213.18
US$ 1033.67
US$ 62.95
US$ 19.95
US$ 2574.00
Sold : Login>>